Type 1 Trial Expands to Include Youngsters
Children as young as 8 years old are now eligible to participate in a nationwide study of teplizumab, a drug that researchers hope will prevent type 1 diabetes in those at high risk. Previously, the study couldn't include anyone under 16 years old, but the Food and Drug Administration ruled that the drug is safe enough to test in younger children. People who have a close relative with type 1 diabetes are eligible to be screened for the study. For more information, go to diabetestrialnet.org.